WFG Advisors’s Avadel Pharmaceuticals AVDL Stock Holding History

WFG Advisors’s Portfolio AVDL Stock Details AVDL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	$6K	Hold	570	–	–	﹤0.01%	1237
2017 Q1	$6K	Hold	570	–	–	﹤0.01%	1171
2016 Q4	$6K	Hold	570	–	–	﹤0.01%	1217
2016 Q3	$7K	Hold	570	–	–	﹤0.01%	1210
2016 Q2	$6K	Hold	570	–	–	﹤0.01%	1201
2016 Q1	$6K	Hold	570	–	–	﹤0.01%	1148
2015 Q4	$7K	Hold	570	–	–	﹤0.01%	1152
2015 Q3	$9K	Hold	570	–	–	﹤0.01%	1115
2015 Q2	$12K	Hold	570	–	–	﹤0.01%	1122
2015 Q1	$10K	Hold	570	–	–	﹤0.01%	1191
2014 Q4	$10K	Hold	570	–	–	﹤0.01%	1452
2014 Q3	$8K	Hold	570	–	–	﹤0.01%	1545
2014 Q2	$9K	Hold	570	–	–	﹤0.01%	1512
2014 Q1	$8K	Hold	570	–	–	﹤0.01%	1505
2013 Q4	$5K	Buy	+570	New	+$4.02K	﹤0.01%	1733

Other funds holding AVDL

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return

FPC

Falcon Point Capital San Francisco, California $11.9M AUM 55.76% 1-Year Est. Return

WFG Advisors's AVDL Position: Q2 2017 in Review

WFG Advisors held its Avadel Pharmaceuticals (AVDL) position steady in Q2 2017 at 570 shares worth $6K. The position accounts for ﹤0.01% of the portfolio, ranked #1237.

WFG Advisors first reported a position in AVDL in Q4 2013 and has held it in 15 quarters since. The position peaked at $12K in Q2 2015. 78 funds tracked by Wall St. Rank hold AVDL as of Q2 2017.

WFG Advisors held 570 shares of Avadel Pharmaceuticals worth $6K as of Q2 2017.
WFG Advisors left its Avadel Pharmaceuticals share count unchanged in Q2 2017.
Avadel Pharmaceuticals made up ﹤0.01% of WFG Advisors's portfolio in Q2 2017, its #1237 holding.
WFG Advisors first reported a position in Avadel Pharmaceuticals in Q4 2013 and has held it in 15 quarters since.
WFG Advisors's Avadel Pharmaceuticals position peaked at $12K in Q2 2015.
78 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q2 2017.

Based on WFG Advisors's 13F filing for Q2 2017, filed 18 Aug 2017.